ARQULE INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$13.7M | −$27.0M | −$22.9M | −$14.2M | −$24.3M | −$25.1M |
| Net income | −$6.5M | −$7.6M | −$5.0M | −$4.6M | −$23.4M | −$24.6M |
| Total assets | $106.7M | $48.9M | $32.4M | $40.0M | $63.4M | $98.2M |
| Total liabilities | $27.7M | $25.9M | $8.7M | $10.8M | $22.8M | $37.6M |
| Equity | $79.0M | $14.2M | $23.7M | $29.2M | $40.5M | $60.6M |
| EPS (diluted) | $-0.07 | — | — | — | — | — |
| Shares out. | 87.1M | 71.1M | 62.9M | 62.8M | 62.9M | 62.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- —
- Net margin
- —
- Return on equity
- −8.3%
- Return on assets
- −6.1%
- Return on capital (ROCE)
- −14.9%
- Liabilities / assets
- 26.0%
- Debt / equity
- 0.35×
- Book value / share
- $0.91
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -8.97distress
- Accruals / assets
- 6.0%moderate
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Messenger William GDirector | Jan 16, 2020 | U | 20,000 | $20.00 |
| Barabe Timothy CDirector | Jan 16, 2020 | U | 146,897 | $20.00 |
| Kelley Susan L.Director | Jan 16, 2020 | U | 50,000 | $20.00 |
| Nussbaum RanDirector | Jan 16, 2020 | U | 2.3M | $20.00 |
| Lindsay Ronald MDirector | Jan 16, 2020 | U | 60,800 | $20.00 |
| Zenner Patrick JDirector | Jan 16, 2020 | U | 122,216 | $20.00 |
| Pucci PaoloOfficer — Chief Executive Officer | Jan 16, 2020 | U | 1.2M | $20.00 |
| Lawrence Peter SOfficer — President and COO | Jan 16, 2020 | U | 314,593 | $20.00 |
| Schegerin MarcOfficer — CFO and Treasurer | Jan 16, 2020 | U | 23,001 | $20.00 |
| Loberg Michael DDirector | Jan 16, 2020 | U | 188,062 | $20.00 |
| Schwartz BrianOfficer — See Remarks | Jan 16, 2020 | U | 289,838 | $20.00 |
| Schamber BlaineOfficer — VP Finance, CAO | Jan 16, 2020 | U | 57,774 | $20.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 16, 2020
- Entered a material agreementDec 17, 2019
- Entered a material agreement · Amended charter or bylaws · Other material eventDec 9, 2019
- Item 5.05Nov 20, 2019
- Results of operationsOct 30, 2019
- Results of operationsAug 7, 2019
- Entered a material agreement · Other material eventJun 25, 2019
- Director / officer change · Shareholder voteMay 14, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ACONSONANCE CAPITAL MANAGEMENT LPFeb 17, 2021
- SC 13G/ACONSONANCE CAPITAL MANAGEMENT LPFeb 16, 2021
- SC 13G/AAMENDMENT NO. 9 TO THE SCHEDULE 13GFeb 14, 2020
- SC 13GCONSONANCE CAPITAL MANAGEMENT LPFeb 14, 2020
- SC 13G/AFeb 12, 2020
- SC 13G/ASCHEDULE 13G/AFeb 12, 2020
- SC 13G/AFeb 10, 2020
- SC 13G/AFeb 5, 2020
- 15-12GJan 27, 2020
- EFFECTJan 17, 2020
- EFFECTJan 17, 2020
- EFFECTJan 17, 2020
- 4OWNERSHIP DOCUMENTJan 16, 2020
- 4OWNERSHIP DOCUMENTJan 16, 2020
- 4OWNERSHIP DOCUMENTJan 16, 2020